▲Hanchang Biotech=Korea Exchange announced that the changed largest shareholder must comply with a one-year lock-up period for approximately 6.2 million new shares acquired through a rights offering.
▲DXNVX=Announced the acquisition of 100% of Korea Biopharm's shares for approximately 15 billion KRW. This is aimed at expanding the bio-industry value chain and creating synergy.
▲PHC=Announced that the COVID-19 rapid diagnostic kit supply contract worth 26.2 billion KRW, signed in September 2020, has been terminated by notification from the contracting party.
▲CODIEM=Announced a reverse stock split where 20 common shares will be consolidated into 1 share of the same par value. This is to improve financial structure through deficit compensation.
▲Magic Micro=Although it was previously informed that the delisting procedure would be suspended pending court confirmation due to an additional injunction application to suspend the delisting effect, it has been announced that the orderly trading process will resume considering that the injunction application dismissed earlier this month is not significantly different.
▲PSMC=Announced that to secure liquidity through financial structure improvement, it will transfer all shares of its subsidiary PSMC PHILIPPINES, INC. to Haesung DS for approximately 12 billion KRW.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
